Agostina Siniscalchi

Chemotherapy plus lenalidomide versus autologous transplantation, followed by lenalidomide plus prednisone versus lenalidomide maintenance, in patients with multiple myeloma: a randomised, multicentre, phase 3 trial

Francesca Gay, Stefania Oliva, Maria Teresa Petrucci et al. · The Lancet Oncology · 2015 · 313 citations · Full text

Medicine, Oncology, Pharmacotherapy +17

Aspirin or enoxaparin thromboprophylaxis for patients with newly diagnosed multiple myeloma treated with lenalidomide

Alessandra Larocca, Federica Cavallo, Sara Bringhen et al. · Blood · 2011 · 286 citations

Medicine, Hematology, Pharmacology +12

Complete response correlates with long-term progression-free and overall survival in elderly myeloma treated with novel agents: analysis of 1175 patients

Francesca Gay, Alessandra Larocca, Pierre W. Wijermans et al. · Blood · 2011 · 268 citations · Full text

Medicine, Oncology, Chemotherapy +8

Characterization of Ph‐negative abnormal clones emerging during imatinib therapy

Elisabetta Abruzzese, Alessandro Gozzetti, Sara Galimberti et al. · Cancer · 2007 · 30 citations

Medicine, Hematology, Oncology +8

Melphalan/Prednisone/Lenalidomide (MPR) Versus High-Dose Melphalan and Autologous Transplantation (MEL200) in Newly Diagnosed Multiple Myeloma (MM) Patients <65 Years: Results of a Randomized Phase III Study

Antonio Palumbo, Federica Cavallo, Izhar Hardan et al. · Blood · 2011 · 24 citations

Medicine, Hematology, Oncology +17